Symetis announces successful, first time implantation of its systems in Japan

The procedures were performed as part of a feasibility study being conducted under the leadership of Professor Yoshiki Sawa. Immediate post-operative results demonstrated excellent outcomes.

Professor Y. Sawa stated: “This is the first time that a second generation TAVI was implanted in Japan and we are proud to lead this clinical effort to bring the ACURATE TAVI systems to our patient population. These cases also marked our 100^th TAVI implantation at Osaka University Hospital.”

Four patients were treated by Professor Toru Kuratani, with two patients receiving a transapical ACURATE TA valve and two patients receiving a transfemoral ACURATE TF valve. Professor T. Kuratani commented on the ease of use of the Symetis products: “The uncomplicated, step-by-step delivery process for both the ACURATE TA and ACURATE TF provides the implanter with full control until final delivery. The positioning is intuitive and the absence of paravalvular leak is impressive”.

The implantations at Osaka University Hospital are part of a feasibility study to support the filing with the Japanese Pharmaceutical and Device Agency (PMDA) for a multi-center pre-market approval study.

Symetis Inc. is a privately-owned Swiss company developing innovative, minimally invasive heart valve replacement solutions. The company’s products, ACURATE TA and ACURATE TF, are based on proprietary geometry and delivery technologies and are well positioned to target the estimated $2 billion TAVI market. Based in Lausanne, the company is financed by leading European venture capital firms, including Truffle Capital, Novartis Venture Fund, Wellington Partners, Aravis Venture, Vinci Capital, Banexi Ventures, Endeavour Vision, NBGI Ventures and BiomedInvest.